2269.HK - WuXi Biologics (Cayman) Inc.

HKSE - HKSE Delayed Price. Currency in HKD
76.500
+0.300 (+0.394%)
At close: 4:08PM HKT
Stock chart is not supported by your current browser
Previous Close76.200
Open76.500
Bid76.500 x 0
Ask76.550 x 0
Day's Range75.050 - 77.700
52 Week Range25.000 - 86.500
Volume3,037,548
Avg. Volume4,366,721
Market Cap93.579B
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est79.21
  • PR Newswirelast month

    WuXi Biologics to Install Industry's Largest Single-Use Bioreactor from ABEC at its New Commercial Manufacturing Facility

    WUXI, China and BETHLEHEM, Pa. , March 20, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...

  • Business Wirelast month

    WuXi Biologics to Install Industry’s Largest Single-Use Bioreactor from ABEC at its New Commercial Manufacturing Facility

    WuXi Biologics , a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has selected 4,000 liter Custom Single Run disposable bioreactors from ABEC for its new commercial manufacturing facility in Wuxi city, Jiangsu, China.

  • PR Newswirelast month

    WuXi Biologics Reports Remarkable 2017 Annual Results: Revenue up 63.7% to a Record High of RMB1,618.8 Million

    HONG KONG, March 19, 2018 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or the "Group", stock code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced its audited annual results for the year ended December 31, 2017 today.

  • PR Newswirelast month

    WuXi Biologics and Adagene Announce Strategic Development and Manufacturing Partnership of New Antibody Therapeutics

    SHANGHAI , March 8, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development ...

  • PR Newswirelast month

    WuXi Biologics Congratulates TaiMed on FDA Approval for Trogarzo

    SHANGHAI, March 6, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today congratulates its partner TaiMed Biologics for receiving approval from the U.S. FDA for Trogarzo (ibalizumab) for the treatment of adult patients living with HIV who have tried multiple HIV medications in the past and whose HIV infections cannot be successfully treated with other currently available therapies. Fewer than 10 global CDMOs (Contract Development and Manufacturing Organization) have so far obtained approval from the U.S. FDA for biological products.

  • PR Newswirelast month

    WuXi Biologics Receives Asia's CMO of 2017 from BioPharma Industry Awards

    SHANGHAI , March 5, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development ...

  • PR Newswire2 months ago

    WuXi Biologics Announces Positive Profit Alert

    SHANGHAI, March 5, 2018 /PRNewswire/ -- WuXi Biologics (Stock Code: 2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics discovery, development and manufacturing, announced that based on the preliminary assessment of the unaudited consolidated management accounts of the Company for the year ended December 31, 2017, the Company is expected to record an increase of approximately 75% to 80% in its net profit from RMB141 million for the year ended December 31, 2016 to an amount of approximately RMB247 million to RMB254 million for the year ended December 31, 2017. During the Reporting Period, the Company incurred an unrealized foreign exchange loss due to a translation loss from the IPO proceeds (in U.S. Dollar) to Renminbi as a result of Renminbi appreciation against the U.S. Dollar.

  • PR Newswire2 months ago

    WuXi Biologics Congratulates MabSpace on FDA Approval of IND for MSB2311

    SHANGHAI , Feb. 26, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development ...

  • PR Newswire2 months ago

    WuXi Biologics Congratulates Tychan for Dosing First Patient of a Zika Antibody after Record 9 Months of Development

    SHANGHAI, Feb. 8, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today congratulated its partner Tychan for dosing the first patient with a first-in-class Zika antibody Tyzivumab in a Phase Ia clinical trial in Singapore. Tychan is a clinical-stage biotechnology company located in Singapore. Enabled by WuXi Biologics, the Investigational New Drug (IND) package for Tyzivumab was developed in a record time of 9 months.

  • PR Newswire3 months ago

    WuXi Biologics Congratulates BioAtla on FDA Clearance of IND Application for CAB-AXL-ADC

    SHANGHAI , Jan. 30, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development ...

  • PR Newswire3 months ago

    WuXi Biologics and Aravive Biologics to Form Strategic Manufacturing Collaboration Following Successful IND Filing for AVB-S6-500

    WUXI, China and HOUSTON, Jan. 29, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Aravive Biologics, Inc., today announced plans to expand their biologics manufacturing collaboration, based on the rapid success achieved in the process development, scale-up and cGMP manufacture of Aravive's lead drug candidate, AVB-S6-500 (previously referred to as Aravive-S6). The decision follows the successful filing of a U.S. Investigational New Drug application (IND) for AVB-S6-500, a novel GAS6-AXL pathway inhibitor which Aravive is developing for the treatment of cancer and non-malignant fibrotic conditions. "Since selecting WuXi Biologics to produce our lead therapeutic candidate for preclinical studies, our efforts with the firm on the production and scale-up of AVB-S6-500 have been extremely successful, quickly advancing from plasmid to U.S. IND in less than 16 months," said Ray Tabibiazar, M.D., Chairman of Aravive.

  • PR Newswire3 months ago

    WuXi Biologics Announces Formation of Scientific Advisory Board

    Internationally Renowned Scientists and Entrepreneurs to Provide Guidance and Insights to Further Advance the Company's Leading Position in Developing Enabling Technologies for Biologics Discovery, Development ...

  • PR Newswire3 months ago

    WuXi Biologics Appoints Dr. Chiang Syin, a Former FDA Officer as Chief Quality Officer

    WUXI, China , Jan. 14, 2018 /PRNewswire/ -- WuXi Biologics (WuXi Bio, 02269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, ...

  • PR Newswire4 months ago

    WuXi Biologics Initiated cGMP Manufacturing in the World's Largest Biologics Manufacturing Facility Using Only Single-Use Bioreactors

    WUXI, China , Dec. 6, 2017 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development ...

  • PR Newswire6 months ago

    WuXi Biologics and Pall Corporation Establish Joint Continuous Bioprocess Laboratory

    Working together to develop next-generation biopharmaceutical manufacturing technologies that may reduce costs of novel antibodies to less than 15 USD /g. SHANGHAI , Nov. 2, 2017 /PRNewswire/ -- WuXi Biologics ...